- Category: Pipeline
Pipeline
Glaukos and RevOpsis partner on retina tri-specific therapy development, commercialization
Exclusive licensing agreement also extends up to four retinal biologics.
Pipeline
Nacuity doses first patient in phase 3 trial on oral therapy for RP associated with Usher syndrome
Sites in the U.S. and Australia are actively enrolling patients for the SLO-RP Preserve trial.
Pipeline
FDA grants Orphan Drug designation to Octant's RP oral therapy
Oral small molecule is designed to correct protein misfolding for RHO gene mutations, the root cause of RHO-adRP; phase 1/2 clinical study currently underway.
Pipeline
Roivant, Priovant report positive phase 3 NIU data for brepocitinib
Oral therapy demonstrates broad and significant benefits in adults with NIU; companies target H1 2027 sBLA submission.
Pipeline
FDA clears Opus Genetics' IND for RDH12-LCA gene therapy
Phase 1/2 clinical trial expected to kick off before the end of the year to evaluate OPGx-RDH12’s potential in treating inherited childhood blindness.
Pipeline
SpyGlass Pharma reports 4-year, FIH data on BIM-IOL System
Company is continuing phase 3 enrollment while working with the FDA toward a future NDA submission.
Pipeline
Eclipse reports positive phase 2 topline data on DME steroid implant
EC-104 demonstrated durability, consistent anatomical response, and a strong safety profile; company eyes pivotal program in 2027.
Pipeline
Stuart Therapeutics submits IND amendment for corneal wound healing
Planned proof-of-concept study is the first expansion beyond DED indication for ST-100 (vezocolmitide), with a phase 2 trial to follow in H2 2027.
Pipeline
EyePoint reports variable outcomes in latest phase 3 DURAVYU wet data readout
LUCIA trial fails to meet primary goal; company to cut workforce reduction by 53% as part of a strategic prioritization to advance phase 3 DME program.
Pipeline
Innovent's Sycume meets phase 3 endpoint for inactive TED
RESTORE-3 trial demonstrates efficacy in reducing proptosis and a favorable safety profile for patients with inactive TED.
Pipeline
Roche reports phase 3 data on steroid-free therapy for UME management
Company announces FDA acceptance of BLA submission as 52-week results find vamikibart demonstrated sustained improvements in vision.
Pipeline
FDA clears Surrozen's IND for DME therapy
First patient dosing in the DUET trial planned for later this year; study will be the first to evaluate humans treated with the bifunctional antibody.
Pipeline
Bausch + Lomb's oral dry AMD therapy advances to clinical evaluation
Company reports a constructive meeting with the FDA over a planned trial evaluating oral tonabersat; currently eyeing a 2027 timeframe for kickoff.
Pipeline
4DMT advances DME gene therapy to phase 3 evaluations
Phase 3 4SIGHT trial has begun enrolling patients and 2-year phase 2 SPECTRA results show over 60% treatment burden reduction.
Pipeline
Aldeyra to formally appeal third reproxalap CRL
Company to submit a formal dispute resolution request following Type A and D meetings with FDA over the investigational DED drop.
Pipeline
Merck releases phase 2b/3 wet AMD data for tri-specific antibody
Topline data demonstrates non-inferiority and higher rates of two AEs and treatment discontinuation due to AEs.
Pipeline
Kodiak's tarcocimab meets wet AMD phase 3 endpoint, targets Q4 BLA
Zenkuda and KSI-501 both met the primary endpoint in DAYBREAK study, accelerating Kodiak’s development plans.
Pipeline
Beacon Therapeutics releases positive topline phase 2 data on laru-zova for XLRP
VISTA is reportedly the first pivotal trial in XLRP to achieve its FDA-endorsed primary endpoint; company plans to submit a rolling BLA later this year.
Pipeline
Sling Therapeutics raises $123M, begins phase 3 dosing for TED therapy
Following significant investment, Sling advances oral small molecule therapy to late-stage clinical trial testing.
Pipeline